Imperial College London
Alternate

ProfessorXiao-NingXu

Faculty of Medicine, Department of Infectious Disease

Chair in Human Immunology
 
 
 
//

Contact

 

+44 (0)20 3315 6558x.xu

 
 
//

Assistant

 

Dr Victoria Male +44 (0)20 3315 3000

 
//

Location

 

Chelsea and Westminster HospitalChelsea and Westminster Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Rijal:2019:10.1016/j.celrep.2019.03.020,
author = {Rijal, P and Elias, SC and Machado, SR and Xiao, J and Schimanski, L and O'Dowd, V and Baker, T and Barry, E and Mendelsohn, SC and Cherry, CJ and Jin, J and Labbé, GM and Donnellan, FR and Rampling, T and Dowall, S and Rayner, E and Findlay-Wilson, S and Carroll, M and Guo, J and Xu, XN and Huang, KYA and Takada, A and Burgess, G and McMillan, D and Popplewell, A and Lightwood, DJ and Draper, SJ and Townsend, AR},
doi = {10.1016/j.celrep.2019.03.020},
journal = {Cell Reports},
pages = {172--186.e7},
title = {Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans},
url = {http://dx.doi.org/10.1016/j.celrep.2019.03.020},
volume = {27},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated with recombinant adenovirus expressing Ebola virus glycoprotein (EBOV GP) and boosted with modified vaccinia virus Ankara. Among 82 antibodies isolated from peripheral blood B cells, almost half neutralized GP pseudotyped influenza virus. The antibody response was diverse in gene usage and epitope recognition. Although close to germline in sequence, neutralizing antibodies with binding affinities in the nano- to pico-molar range, similar to “affinity matured” antibodies from convalescent donors, were found. They recognized the mucin-like domain, glycan cap, receptor binding region, and the base of the glycoprotein. A cross-reactive cocktail of four antibodies, targeting the latter three non-overlapping epitopes, given on day 3 of EBOV infection, completely protected guinea pigs. This study highlights the value of experimental vaccine trials as a rich source of therapeutic human monoclonal antibodies.
AU  - Rijal,P
AU  - Elias,SC
AU  - Machado,SR
AU  - Xiao,J
AU  - Schimanski,L
AU  - O'Dowd,V
AU  - Baker,T
AU  - Barry,E
AU  - Mendelsohn,SC
AU  - Cherry,CJ
AU  - Jin,J
AU  - Labbé,GM
AU  - Donnellan,FR
AU  - Rampling,T
AU  - Dowall,S
AU  - Rayner,E
AU  - Findlay-Wilson,S
AU  - Carroll,M
AU  - Guo,J
AU  - Xu,XN
AU  - Huang,KYA
AU  - Takada,A
AU  - Burgess,G
AU  - McMillan,D
AU  - Popplewell,A
AU  - Lightwood,DJ
AU  - Draper,SJ
AU  - Townsend,AR
DO  - 10.1016/j.celrep.2019.03.020
EP  - 186
PY  - 2019///
SN  - 2211-1247
SP  - 172
TI  - Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans
T2  - Cell Reports
UR  - http://dx.doi.org/10.1016/j.celrep.2019.03.020
UR  - https://www.sciencedirect.com/science/article/pii/S2211124719303274?via%3Dihub
UR  - http://hdl.handle.net/10044/1/96333
VL  - 27
ER  -
Download